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1. ABSTRACT
Stem cells are being used in the treatment 
of cardivovascular diseases. Here, we review the 
physiologic and pathologic conditions that impact the 
regenerative potential of stem cells in the treatment of 
cardiovascular diseases which include the influence of 
donor age and the presence of metabolic syndromes. 
We will also discuss strategies such as pretreatment 
of the recipient tissue or autologous or allogeneic stem 
cells by growth factors or drugs and by providing a 
synthetic scaffold and genetic modifications that impact 
the regenerative potential of stem cells. Finally, we will 
evaluate the current state of treatment of acute or chronic 
cardiovascular diseases with allogeneic stem cells.
2. INTRODUCTION
Ischemic heart failure is the leading cause of 
hospitalization and death in Western countries (1, 2). 
So far, the employment of current clinical therapies has 
been useful to slow the progression of cardiovascular 
diseases, however the regeneration of hearth tissue after 
an ischemic insult is still to be solved. Stem cell therapy 
has proven to be a promising option for the treatment of 
cardiovascular diseases of ischemic origin, by promoting 
cardiac tissue regeneration (3). Cardiac function and 
cardiomyogenic and vascular cell lineage differentiation 
have been improved by both bone marrow (BM)-derived 
and tissue specific stem cells in experimental models. 
Additionally, the capacity of stem cells to secrete 
paracrine pro-angiogenic and cardioprotective molecules 
has also been demonstrated. Although BM-derived 
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cells are the most used cell type in cell therapy-based 
applications, non-BM or tissue specific stem cell types 
including mesenchymal stem cells (MSCs), endothelial 
progenitor cells (EPCs), hematopoietic stem cells (HSCs) 
and cardiac tissue derived progenitors (CPCs) are also 
under clinical evaluation.
A major limitation in the field of cell therapy 
is determined by the fact that the functionality of stem 
cells largely depends on the pathophysiological state of 
the donors. Metabolism is known to markedly influence 
stem cell fate and function (4). Indeed, aging, metabolic 
syndrome and diabetes represent major changes in 
metabolism that are associated with cardiovascular 
diseases and affect the quantity and quality of stem 
cells, thus limiting their therapeutic potential. In light of 
this, several research groups are currently attempting to 
further investigate this major issue. Presently, three main 
strategies have been proposed: 1) development of pre-
conditioning treatments to restore or improve the function 
of ‘sick’ cells before their reinfusion, 2) preparation of the 
recipient tissue by treating the patient in order to increase 
the engraftment of transplanted cells, 3) use of allogeneic 
rather than autologous cells.
2.1. Stem cells for cardiac regeneration
Stem cells hold the ability to self-renew and 
to differentiate into multiple lineages according to their 
degree of stemness. Over the years accumulating 
evidences have suggested that almost all tissues (heart, 
adipose, brain, spleen, liver, kidney, lung, muscle, thymus, 
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pancreas, umbilical cord, placenta, dental pulp, skin and 
a variety of fetal tissues) retain niches of “resident” stem 
cells similar to those observed in BM (4,5). Consequently, 
the discovery of a cardiac stem cell (CSC) niche residing 
in the adult heart has changed the dogma that the 
heart is a post-mitotic organ devoid of regeneration 
potential (5). CSCs have been proven to self-renew, 
to possess clonogenic and multipotent ability and to 
differentiate both in vitro and in vivo into cardiomyocytes, 
smooth muscle cells and endothelial cells (5-10). Indeed, 
since the first discovery of c-kit+ CSCs, different types of 
CSCs and cardiac progenitor cell populations have been 
identified both in rodents and humans (5, 9, 11), including 
a mixed population named cardiospheres containing 
c-kit+ cells and cells expressing the stromal cell marker 
CD105 (12). Human c-kit+ CSCs are the first cardiac 
resident population which has been used in a clinical 
trials (SCIPIO and CADUCEUS). The SCIPIO trial is a 
randomized phase I trial testing the safety and feasibility 
of using autologous c-kit+ CSCs to treat ischemic 
cardiomyopathy. Despite the small number of patients 
enrolled, the trial has demonstrated that the infusion of 
CSCs is safe and feasible, reduces infarct size, improves 
regional and global LV function and the viability of the 
myocardium for up to 1 year after injection (13, 14). 
A second phase I trial named CADUCEUS, based on 
the use of human cardiosphere derived cells (CDCs), 
which contain c-kit+ CSCs, has been conducted to 
improve safety and to verify the preliminary efficacy of 
intracoronary administration of autologous CDCs. The 
results of the CADUCEUS trial has proven that the use of 
CDCs is safe resulting in decreased scar size, increased 
myocardium viability and improved regional function of 
the infarcted myocardium 1 year post-treatment (15).
Despite this, it is hard to undoubtedly assess the 
best stem cell source to repair a damaged heart. In fact, 
besides CDCs and CSCs, other non-cardiac stem cell 
populations have been undergoing clinical evaluation. 
However, BM-derived cells (including HSCs, MSCs and 
EPCs) and adipose tissue derived mesenchymal stem 
cells (A-MSCs) still represent the main cell types that have 
been studied to regenerate a damaged myocardium.
Human HSCs, identified by the expression 
of surface markers such as CD133, CD34, or CD117 
(c-kit), have been demonstrated to exhibit in vitro trans-
differentiation ability towards myocardial lineages and 
therefore are intensively studied for the treatment of 
cardiac failure (16). Clinical trials conducted so far, using 
BM-derived HSCs have proved the safety and feasibility of 
this cell population for cardiac applications (8). Similarly, 
EPCs (another BM-derived stem cell population) have 
been extensively investigated for cardiac regenerative 
purposes (17). EPCs are angiogenic cells capable of 
differentiating into mature endothelial cells and promote 
the repair of damaged endothelium (18, 19). Several 
clinical trials have tested the use of these cells in the 
treatment of cardiovascular diseases. TOPCARE-AMI 
is the first randomized clinical study examining the use 
of EPCs for the treatment of acute myocardial infarction. 
This study has demonstrated that EPCs are able to 
enhance left ventricular ejection fractions and to reduce 
infarct size in the absence of cardiac hypertrophy (20); 
in a similar setting, REPAIR-AMI has demonstrated that 
transplantation of EPC abrogates early LV remodeling 
after AMI. The MAGIC and BOOST trials have shown 
regeneration and angiogenesis after G-CSF and intra-
coronary BM-mononuclear cell infusion in patients with 
myocardial infarction (21-23).
An increasing body of evidence suggests that 
non EPC-like cells such as MSCs represents a promising 
stem cell source, particularly suitable for regenerative 
medicine applications. MSCs have been identified 
as a multipotent population showing plastic-adherent 
properties, ability to generate single-cell colonies (24) 
and mesodermal differentiation potential (chondrogenic, 
adipogenic and osteogenic differentiation) (25-27). To 
date, MSC phenotype cannot be identified by a specific 
single marker. Accordingly, in 2005 the International 
Society for Cellular Therapy (ISCT) published a position 
paper, defining the minimum criteria to define the MSC 
population; positive for CD73, CD90 and CD105 and 
negative for hematopoietic markers, such as CD45, 
CD34 and CD19 (28). Intriguingly, MSCs have been 
demonstrated to differentiate towards the cardiac lineage 
both in vitro and in vivo (26, 29-39) and the interest for this 
cell type is increasing due to their immune-modulating 
properties. Thus, MSCs are under investigation to test 
both autologous and allogeneic use in different clinical 
trials. Currently, autologous and allogeneic MSCs are 
examined in the POSEIDON-DCM trial as treatment 
options for non-ischemic heart failure.
Among the non BM-derived stem cells, a growing 
interest is focused on adipose tissue-derived stem cells 
(A-MSCs) described for the first time by Zuk et al. in 
2001 (28). A-MSCs have been located in the vessel 
walls and perivascular niches (40) present in fat obtained 
during liposuction (a minimally invasive and low risk 
procedure). Interestingly, A-MSCs share many features 
with BM-derived MSCs. Indeed, with the exception 
of the surface marker CD34 (41), A-MSCs possess 
all the minimal criteria defined by ISCT for identifying 
MSCs (27, 28). Several studies have reported the ability 
of rabbit, mice and human A-MSCs to differentiate in vitro 
into cardiomyocytes under specific culture conditions (42-
47). Moreover, in some cases, A-MSCs have also been 
shown to acquire pacemaker activity, although at low 
percentages (48). Similarly to BM-derived MSCs, A-MSCs 
improve cardiac function in rodent and pig models of MI, 
although it is unclear whether their beneficial activity is 
mainly the result of direct trans-differentiation into new 
cardiomyocytes, endothelial and smooth muscle cells 
or the indirect consequence of their paracrine action in 
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combination with their ability to exert a feeder-like support 
within the cardiac tissue (26, 49-54). Several phase I/II 
studies are currently ongoing to test the safety, feasibility, 
and efficacy of A-MSCs in cardiovascular diseases. 
APOLLO and PRECISE trials using freshly isolated 
A-MSCs have reported a trend for increased cardiac 
function in terms of perfusion, reduction of scar (APOLLO 
trial) and increased wall motion score index evaluated by 
magnetic resonance (PRECISE trial) (55, 56), whereas 
MyStromalCell Trial has tested the intramyocardial (IM) 
injection of culture-expanded A-MSCs stimulated with 
VEGF-A165 (57). The ADVANCE study was the first trial 
to evaluate the efficacy of A-MSC-based cell therapy 
in patients with AMI. Patients were treated or not with 
A-MSCs and the amount of infarct size reduction was 
assessed at 6 months (58). Unfortunately, the trial was 
terminated due to difficulties in recruiting patients and 
reaching the target enrollment of 216 patients which 
stood at 23 patients when the trial was terminated.
3. PHYSIOLOGICAL CONDITIONS 
INFLUENCING STEM CELL REGENERATIVE 
POTENTIAL OF STEM CELLS
There is compelling evidence that aging, 
metabolic and cardiovascular diseases are critically 
interconnected. Indeed, patients experiencing metabolic 
and cardiovascular diseases age faster. Furthermore, 
a clear association between cardiovascular risk and 
increased age has been largely reported (59). The 
average lifespan of humans is increasing, and the 
percentage of older people will continue to grow in 
the next 20 years. Therefore it is easily estimated that 
cardiovascular diseases will still represent the leading 
cause of death in people over 65 years of age (60). The 
scientific literature to date suggests that metabolism 
can profoundly influence the fate of stem cells (61-65). 
As a consequence, natural or pathological changes 
in metabolism associated with natural aging or with 
metabolic diseases of donors are predicted to negatively 
impact the quantity and quality of stem and progenitor 
cells, thus limiting their therapeutic potential (66-69).
3.1. Aging
Aging is a physiological process that affects 
all organs and tissues, leading to the deterioration of 
their normal function and to the inhibition or impairment 
of repair mechanisms. Indeed, the functionality of adult 
stem cells decreases with age which impact the normal 
tissue regeneration rate (68, 70,71-73). Myocardial aging 
has been proposed as an imbalance between the growth 
and death of myocytes, resulting in the accumulation 
of senescent myocytes with decreased contractile 
function (74). Cell senescence affects not only myocytes 
but also CPCs (74). In fact, cardiac aging correlates with 
a decreased number of active resident stem cells that 
display shorter telomeres, increased genomic instability, 
DNA damage, p53 activation and consequent cell cycle 
arrest (75, 76). Aged CPCs acquire the senescent 
phenotype and irreversible growth arrest demonstrated 
by the in vivo expression of the associated protein 
p16INK4a. Consequently, cardiac aging is associated 
with the formation of dysfunctional niches where an 
imbalance between dividing and senescent CPCs is 
observed, ultimately altering both tissue and organ 
homeostasis (77). Moreover, aging has been reported 
to influence tissue oxygenation by unbalancing the ratio 
between hypoxia (required for long-term preservation 
of undifferentiated CPCs) and normoxia (required for 
active cardiomyogenesis typical of young CPCs), thus 
exacerbating the accumulation of fibroblasts in hypoxic 
foci and increased plasma levels of the advanced glycated 
end product N’-carboxymethyl lysine (CML) (78).
Cardiac progenitor cells nested in this 
unbalanced and unfavorable microenvironment, are not 
able to re-enter the cell cycle (77). The decrease in tissue 
homeostasis results in the accumulation of senescent 
cardiomyocytes, thus compromising ventricular 
contractile function. In addition, aging negatively acts 
on CPC survival and migration, although the effect 
on growth is controversial (31, 35, 36). Confirmatory 
clinical studies have highlighted the poor efficiency in 
proliferation and differentiation of CPCs isolated from 
older donors compared to younger donors. Accordingly, 
the administration of old versus young cells in an animal 
model of MI, was associated with a reduced therapeutic 
potential of the treatment (33).
From a molecular standpoint, three main 
receptors appear to be involved in CPC senescence and 
the development of myocardial aging: IGF-1/IGF-1R, 
HGF-c-Met and the rennin angiotensin system (RAS). 
In the heart, activation of IGF-1/IGF-1R signaling is 
associated with CPC division, increased telomerase 
activity, prevention of replicative senescence and 
consequent better maintenance of the CPC pool (79-81). 
The expression of IGF-1R and IGF-1 synthesis are 
attenuated in the aged CPCs, negatively impacting 
telomere length and oxidative damage susceptibility (82). 
Indeed, IGF-1 is able to interfere with ROS generation 
and has been shown to decrease oxidative damage 
in the aging myocardium (77). ROS generation and 
accumulation of oxidative DNA damage in aged CPCs 
is associated with Ang II production (83) followed by the 
shortening and uncapping of telomeres (84). Aging also 
decreases Hepatocyte Growth Factor HGF production 
mainly affecting CPC migration ability, (in terms of the 
numbers and speed of CPC migration), by modulating 
their ability to move towards the damaged area and to 
promote heart regeneration (83, 85, 86). Despite this, 
BrdU incorporation experiments performed in the apex 
and atrium of senescent hearts revealed the presence 
of functionally competent CPCs which are responsive to 
growth factors and have preserved telomeres and are 
partially capable of reverting aging myopathy (83).
Aging and metabolic syndrome in stem cell treatment
 1129 © 1996-2016
The influence of aging on stem cell function 
has also been reported in stem cell populations of 
non-cardiac-origin such as in A-MSCs. Aging affects 
the multilineage differentiation potential of A-MSCs as 
well as their proliferation capacity, cellular senescence 
and ability to produce paracrine factors. It has been 
shown that A-MSCs from aged patients have increased 
telomere shortening, decreased ability to stimulate the 
production of capillary-like tubes by endothelial cells 
and decreased secretion of pro-angiogenic factors such 
as VEGF, PGF, HGF, angiopoetin-1 and angiogenin. 
Furthermore, aging has been also associated with the 
abnormal expression of DNA damage repair genes and 
increased CHEK1 and p16INK4a which are involved 
in senescence (87, 88). Similarly, aging leads to a 
functional impairment of BM-MSCs, as shown by the 
limited ability to secrete angiogenic factors, reduced 
regenerative potential (88) and by the inability to induce 
neo-angiogenesis after MI (89). Moreover, cells from 
old patients exhibit reduced tolerance to ischemia, in 
terms of survival in ischemic muscle, compared to young 
patients (90).
Moreover, aging can impact the mobilization 
capacity of BM cells after acute myocardial infarction 
(AMI) in humans (91) resulting in a decreased number of 
CD34+ cells in peripheral blood (92). Preclinical studies 
analyzing the angiogenic response of young cells in the 
aged heart, showed that the aged heart is rejuvenated 
when cardiac endogenous BM cells are replaced with 
young BM cells in a model of parabiosis (93). Telomere 
shortening and replicative exhaustion has also been 
observed in aged HSC populations (83, 94). HSCs 
display impaired migration and lineage commitment 
potential with decreased hematopoiesis and 
lymphopoiesis (83, 95-97). In particular, a similar 
impairment in CPC and HSC migration in response to 
specific stimuli, such as stromal derived factor (SDF-1) 
and VEGF (83, 97) has been observed. Aging has been 
associated with a reduction in the number and function 
of circulating EPCs (98). Furthermore, only EPCs from 
young patients are incorporated into the neovascolature 
and are able to restore angiogenic functions in 
the heart (99).
In conclusion, these observations clearly 
demonstrate that aging represents a critical factor 
influencing the regenerative potential of adult stem cells 
and therefore their possible use in cardiac regenerative 
medicine.
3.2. Metabolic syndrome
Metabolic syndrome includes several diseases 
such as insulin resistance, impaired glucose tolerance, 
type 2 diabetes, dyslipidemia, obesity, high blood pressure 
dyslipidemia, microalbuminuria, which are all associated 
with an increased risk of coronary artery disease (CAD) 
linked to aging (7, 100). Patients with metabolic syndrome 
are 3-4 times more likely to develop type II diabetes and 
the risk of developing cardiovascular disease is almost 
tripled (101). Mansilla et al., firstly proposed metabolic 
syndrome as an exhaustive syndrome of the stem cell 
pool, where defects in specific biological mechanisms 
of stem cells are strictly linked to the progression of the 
syndrome itself (102). In fact, the persistent inflammatory 
state (increased levels of IFN-α, IL-6) developed in 
metabolic syndrome leads to the continuous recruitment 
of the stem cell pool from their tissue of origin, thus 
causing pool exhaustion (102). Specifically, several 
evidences have highlighted a correlation between 
increased oxidative stress, telomere shortening and 
reduced function of circulating EPCs (103). Accordingly, 
a low percentage of circulating EPCs (40% less than 
controls without metabolic syndrome) was found in 
healthy men with abdominal obesity and metabolic 
syndrome (101). The decrease in the endogenous EPC 
pool observed in metabolic syndrome seems to accelerate 
the development of cardiovascular disease (102).
Metabolic syndrome also negatively impacts 
CPC activity and regenerative ability (104-106). One 
possible mechanism is related to the deregulation of 
intracellular Ca2+ levels due to the downregulation of 
Inositol 1,4,5-trisphosphate receptors (IP3Rs) and the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
which in turn influences both CPC proliferation and the 
overall regenerative capacity of the myocardium (107).
Among all conditions that contribute to the 
development of metabolic syndrome, type 2 diabetes is 
the most frequent. Interestingly, diabetic cardiomyopathy 
has been proposed as a CPC disease whose 
abnormalities lead to an imbalance between cell death 
and tissue regeneration (104). Noteworthy, cell death of 
mature cardiomyocytes, SMCs and ECs represent only a 
secondary phenomenon since CPC exhaustion precedes 
the progression of diabetic myopathy (104). Indeed, the 
metabolic pathways supporting CPC function has been 
reported only very recently. Salabei et al. have shown 
that murine CPCs expressing high levels of the glucose 
transporter Glut-1 largely depend on the extracellular 
glucose concentration for their glycolytic rate, thus 
suggesting that CPCs could be prone to hyperglycemic 
injury (40). Another protein playing an important role in 
diabetic myopathy is the p66shc protein, lack-of-which 
has beneficial effects on both viability and function of 
CPCs, and enhances cardiomyocyte differentiation (104). 
Hyperglycemia is also linked to O-glycosylation of proteins, 
including the activation of p53 which is able to up-regulate 
the renin-angiotensin system, conducive to the synthesis 
of angiotensin II (Ang II), resulting in increased cytosolic 
calcium-induced generation of reactive oxygen species 
(ROS) and apoptosis (108). ROS formation initiates DNA 
damage, telomere shortening, irreversible growth arrest 
and cell senescence (84). The impairment of the CPC 
pool in the heart due to hyperglycemia ultimately leads 
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to the accumulation of old and dying cardiomyocytes 
with consequent clinically relevant defects in contraction. 
Moreover decreased muscle mass and dilation of the 
heart chambers contributes to ventricular function 
deficits (104).
The relation between glucose and cardiac 
metabolism is extremely relevant. In the cardiac tissue, 
glucose metabolism plays a key role both in physiological 
and pathological conditions (109). For instance, the 
pentose phosphate pathway, is important for maintaining 
contractility and the redox state of cardiomyocytes, 
generating NAPDH which in turn acts as an alternative 
substrate to anabolic glycolysis. Importantly, CPCs 
isolated from hearts of diabetic mice followed by culture 
in high glucose media, display reduced activity in key 
enzymes of the pentose phosphate pathway (glucose-6-
phosphate dehydrogenase (G6PD) and trans-ketolase) 
resulting in the accumulation of glucose-induced 
Advanced Glycation End-products (AGEs), inhibition 
of pro-survival pathway Akt/Pim-1/Bcl-2 and activation 
of apoptosis (110). Similar phenomena also occur in 
CPCs isolated from diabetic hearts reconditioned with 
physiologically normal glucose levels, confirming the 
concept of the existence of a metabolic memory as a 
consequence of previous exposures to high levels of 
glucose (110). In human diabetic hearts, the number 
of CPCs is reduced also showing less proliferative 
and regenerative capacity compared to non-diabetic 
patients (110, 111). Cells derived from diabetic patients 
and cells preconditioned with high glucose exhibit 
reduced pro-angiogenic capacity that is restored 
following treatment with glyoxalase-1, suggesting that 
the defect can be linked to the accumulation of reactive 
dicarbonyls (111). Comparative studies have also shown 
that CSCs cultured in high glucose concentrations are 
still able to improve heart function in terms of LVEF but 
to a lesser degree than CSCs grown in normoglycemic 
medium (111).
Similar observations have also been reported 
in cardiac derived MSCs (C-MSCs). In a rat model 
of chronic myocardial infarction, C-MSCs have been 
shown to contribute to cardiac repair and display better 
persistence, migration and differentiation properties 
as compared to BM cells isolated from the same 
patients (112). Interestingly, C-MSCs derived from 
patients with diabetes Mellitus (DM C-MSCs) have shown 
a reduced rate of proliferation, premature senescence 
(identified by the positive staining for beta-galactosidase 
and increased p21wa61 protein expression, respectively). 
Furthermore, diabetic C-MSCs display a decreased 
ability to differentiate along adipogenic, endothelial and 
cardiac lineages when compared to C-MSCs isolated 
from normoglycemic patients (113).
Long-term defects in type 2 diabetes have 
also been associated with damage in A-MSC function. 
Cramer et al. have shown that high levels of glucose 
reduce the proliferative capacity of A-MSCs isolated both 
from diabetic (dA-MSCs) and non-diabetic (nA-MSCs) 
donors, however the influence was more significant in 
dA-MSCs. This phenomenon seems to be reversible only 
in nA-MSCs, where there is an increase in proliferative 
capacity after insulin treatment, unlike the dA-MSCs that 
instead showed increased senescence and apoptosis. 
Furthermore, elevated glucose levels influence 
A-MSC differentiation, reducing the osteogenic and 
chondrogenic potential and increasing the adipogenic 
commitment (114).
A similar scenario has been demonstrated 
in other stem cell types. For instance, both type 1 
and type 2 diabetes are associated with reduced 
levels (mean reduction of 40%) and poor functioning 
circulating EPCs (115-117). The number of EPCs 
inversely correlates with glycated hemoglobin (HbA1c) 
levels (118-120) and with fasting glucose levels. In 
particular, a decreased number of CD34+/KDR EPCs 
have been reported to inversely correlate with the 
severity of diabetic vasculopathy (121). EPCs from 
patients with type 2 diabetes mellitus (DM), have shown 
impaired proliferation (important for amplifying the pool of 
endothelial cells), tubulization (necessary to create new 
vascular structures), adhesion to activated endothelium 
(critical for the recruitment of circulating EPCs to the site 
of interest) and migration toward cytokine gradients (such 
as G-CSF). Interestingly, these defects are not reverted 
by normoglycemic cell culture conditions (122, 123). 
However DM does not impact different properties of 
EPCs such as adherence to fibronectin, collagen and 
quiescent endothelial cells (67, 116). More importantly, 
the hyperglycemic-induced alterations in EPC function 
are mediated by pathophysiological mechanisms 
such as inflammation, oxidative stress, altered Akt 
pathway signaling and nitric oxide (NO) have been 
reported on multiple levels: mobilization from BM, 
trafficking and survival in the circulation, homing and 
neovascularization (67). From a molecular standpoint, 
a possible explanation of EPC defects could be the 
activation of MAP kinases, such as p38 that decrease 
the proliferation and differentiation capacity of EPCs 
in culture (124), increasing EPC senescence and 
apoptosis. In DM, increased levels of SDF-1 in the 
BM (due to increased CD26/DPP-4) and decreased 
SDF-1 production in the ischemic tissue is conducive 
to a decrease in the SDF-1 gradient which is normally 
responsible of mobilizing EPCs from the BM into the 
circulation (125-127). It has been shown that the long-
term in vitro exposure to high glucose concentrations, 
inhibits the proliferative capacity, EPC migration and 
the capability of colony formation (128, 129). In these 
conditions a decrease in NO and vascular endothelial 
growth factor (VEGF) secretion in combination with 
a reduction in the activity of superoxide dismutase 
(SOD) have been found. Therefore, it is clear that the 
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defects observed in diabetic EPCs are certainly due 
to the toxic effects of high glucose. However, strict 
glucose control in DM patients had no significant effect 
on the rates of major cardiovascular events, death, or 
microvascular complications (130-132). When used in 
animal models of ischemia, diabetic-EPCs were less 
effective in restoring blood flow compared to cells derived 
from healthy controls (124). In addition, in diabetic 
mice, injection of BM-MNCs from healthy controls was 
more effective than BM-MNCs from diabetic patients. 
As observed in EPCs, BM-MNC dysfunction has been 
associated with an in vitro impairment of differentiation 
capacity and in vivo defects in the formation of vascular-
like structures in Matrigel® plug experiments (133). 
Moreover diabetic BM-MNCs are not able to improve 
cardiac function following injection into a mouse model of 
MI unlike control BM-MNCs (134).
4. STRATEGIES TO ENHANCE STEM CELL 
REGENERATIVE POTENTIAL
The literature reviewed in the previous sections 
clearly indicate that factors such as age, metabolic 
syndrome and diabetes negatively influence the 
regenerative capacity of stem and progenitor cells used for 
cell therapy. The development of innovative approaches 
to improve the engraftment and regenerative potential 
of stem cells is a critical challenge for the successful 
employment of cell therapy in the cardiovascular 
context. To remedy this, three main strategies have been 
proposed: 1) the development of treatments to restore 
or to improve the function of ‘sick’ cells before their 
reinfusion in the damaged heart, 2) the preparation of 
the recipient tissue by treating the patient with drugs able 
to increase the engraftment of transplanted cells, 3) the 
infusion of allogeneic rather than autologous cells.
4.1. Pretreating stem cells before their 
reinfusion
The rationale of this approach consists the 
activation or enhancement of specific molecular pathways 
able to improve the response of stem cell progenitors to 
stress or enhance their regenerative abilities following 
the in vivo injection in the damaged tissue. Stem cells 
are commonly treated after their isolation, during in vitro 
expansion and before their injection into the site of 
injury. In this section we will review some of the most 
representative examples of cell pretreatment-based 
protocols that are currently employed including: growth 
factors, drugs, viral transduction and tissue engineering 
based approaches.
Statins are drugs that inhibit the synthesis 
of endogenous cholesterol by acting on the 
hydroxylmethylglutaryl CoA-reductase. Several studies 
have suggested that statins benefit patients with 
ischemic and non-ischemic cardiomyopathies (135). 
Statins exert pleiotropic effects with different outcomes 
depending on the target cell, the type of statin, and 
the concentration and timing of treatment. Most of the 
studies regarding the effect of statins on stem cell biology 
have been performed on EPCs and MSCs. Systemic 
administration of statins has been shown to normalize 
EPC levels, restore their endothelial regenerative 
capacity and reduce the cardiovascular risk in subjects 
with metabolic syndrome (101). Statins increase the 
bioavailability of NO and reduce EPC apoptosis and 
oxidative stress (136). Moreover, statin treatment delays 
EPC aging by increasing the expression and activity of 
the telomere-capping protein TRF2 and cell cycle cyclins, 
and decreases the cell cycle inhibitor p27Kip1 (137, 138).
Another treatment able to improve EPC function 
is represented by the administration of growth factors. 
Insulin growth factor 1 (IGF-1) increases the number of 
circulating EPCs, enhancing their colony formation ability, 
migratory capacity and the incorporation into tubular-like 
structures (139). Notably, either alone or in combination 
with hepatocyte growth factor (HGF), the IGF-1 treatment 
has been also proven to induce a beneficial effect, by 
acting on CPC division and differentiation after injection 
in a rat model of MI (83). Similarly, when administrated 
systemically, stem cell factor (SCF) has been shown to 
partially activate CPCs in situ reversing myocardial aging 
in mice (77). Additionally the administration of Placenta 
Growth Factor (PlGF) has been shown to increase the 
in vivo mobilization and recruitment of BM derived stem 
cells in a diabetic murine model of hindlimb ischemia. 
PlGF also improves EPC differentiation both in vitro and 
in vivo, increasing neovascularization and blood flow 
recovery in treated versus untreated diabetic mice (133). 
The decrease of endothelial nitric oxide synthase (eNOS) 
observed in diabetic EPCs has been shown to be rescued 
by hyperoxia treatment, or by SDF-1 administration, which 
is able to increase the neovascularization and wound 
healing in animal models (70, 140). Insulin in diabetic 
patients can increase the number of circulating EPCs, 
to boost their in vitro growth and angiogenic potential, 
VEGF production and mobilization (125). This effect is 
enhanced in the presence of the SDF-1 3’-A/G allele, a 
polymorphism in SDF-1 gene associated with increased 
EPC mobilization (141).
A possible alternative to growth factors is 
represented by the use of drugs, reported as particularly 
beneficial to ‘correct’ the detrimental influence that 
metabolic syndrome and/or diabetes have on stem 
cell function. Benfotiamine (BFT), a synthetic S-acyl 
derivative of thiamine (vitamin B1), has been shown 
to reactivate the pentose phosphate pathway, which is 
reduced in the diabetic context, restoring the function of 
CPCs in the heart (110). Similarly, the histone acetylase 
(HAT) activator pentadecylidenemalonate 1b (SPV106), 
has been shown to help the function of diabetic C-MSC, 
improving their proliferation, differentiation capacity and 
histone modifications which are compromised in patients 
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with type 2 diabetes (113). Methylglyoxal (MG), that is a 
reduced derivative of pyruvic acid, accumulates in diabetes 
and impairs neovascularization. The overexpression of 
MG-metabolizing enzyme glyoxalase-1 (GLO1), is able to 
revert the detrimental effects of diabetes in BM-cells (142) 
and CPCs (111), restoring their proangiogenic capacity. 
Other drugs can act by amplifying the number and 
function of EPCs in type II diabetes; Angiotensin II 
type 1 Receptor Blockers ARBs increase the number of 
EPCs (143); agonists of PPAR-γ act through the PI3K/Akt 
pathway (144); the thiazolidinediones activate the Akt/
eNOS pathway; ephrin-B2/Fc (145), and DDP-4 inhibition 
augments the in vitro number (146), migration capability 
and regenerative capacity of EPCs (147, 148); whereas 
G-CSF (149), erythropoietin (150), estrogen (151) and 
VEGF (152) act as mobilizing agents (153). Hydrogen 
sulfide, is able to enhance wound healing in type II 
diabetes patients by restoring EPC function and 
increasing the levels of angiopoietin-1 (154).
Different strategies based on genetic or 
molecular modifications of stem cells have also been 
proposed. For instance, the inhibition of p38-kinase by 
SB203580 (a pyridinyl imidazole inhibitor of p38-kinase) 
or by infection with a dominant negative p38-kinase 
adenovirus or adiponectin (155) is able to act on EPC 
proliferation and differentiation in diabetes. Indeed, 
inhibition of p38 promotes the differentiation of EPCs 
to the endothelial lineage rather than the monocyte-
macrophage lineage and it increases VEGF levels 
which is largely demonstrated to play a key role in 
angiogenesis (70, 124). Alternatively, the molecular 
regulation of EPC function, which is physiologically 
compromised in diabetic patients, may reside in the 
regulation of miRNA 126 and 130a, normally altered in 
diabetes (156, 157) and recently proposed as a novel 
therapeutic target.
Interestingly, the strategy of pretreating stem 
cells with drugs to improve stem cell regenerative 
potential has also been successfully assessed in 
A-MSCs. Natural agents such as curcumin, extracted 
from the spice turmeric has been reported to exhibit 
antioxidant and anti-inflammatory properties (158, 159). 
In a rat model of myocardial ischemia-reperfusion injury 
(IRI), transplantation of curcumin pretreated A-MSCs not 
only improves heart function, higher cell retention, smaller 
infarct size, but also decreases myocardial apoptosis and 
promotes neovascularization and increased VEGF levels 
in the peri-infarcted area (160).
Finally, a triple approach based on the 
combination of tissue engineering, stem cells and drugs is 
now under clinical evaluation, such as the use of scaffolds 
to enhance stem cell engraftment. A-MSCs embedded in 
a scaffold of platelet-rich fibrin (PRF) have been shown 
to significantly promote angiogenesis, to preserve 
wall thickness and heart function, as well as to reduce 
infarct size, LV chamber size, and LV remodeling  (161). 
Similarly, the use of alginate hydrogels has been 
demonstrated to augment the retention of A-MSCs after 
their injection in patients with ischemic heart disease 
without affecting their paracrine potential (162). The use 
of A-MSCs conjugated with VEGF-releasing poly lactic-
co-glycolic acid (PLGA) and pharmacologically active 
microcarriers (PAMs) has resulted in their increased 
proliferation, angiogenic differentiation and VEGF 
production, as well as in decreased cell death compared 
to unconjugated A-MSCs. Similarly, A-MSCs conjugated 
with VEGF-releasing PAMs could have therapeutic 
applications in treating patients with vascular disease, 
including those with a previous AMI (163). In fact, in a 
murine model of AMI, the transplantation of A-MSCs 
conjugated with VEGF-releasing PAMs into the ischemic 
region has already been shown to improve post-AMI 
cardiac function and to increase arteriogenesis. Lastly, 
a significant improvement of the efficacy of stem cell 
regenerative activity has also been demonstrated 
using hydrogels suitably modified, in order to allow the 
controlled release of NO by MSCs, thus enhancing their 
therapeutic efficacy in the treatment of MI (164).
4.2. Treatment of target tissue: how to 
rejuvenate cardiac tissue
As already discussed, aging and metabolic 
dysfunctions have a detrimental effect not only on stem 
cells but also on tissue function, highlighting the critical 
role of the cardiac microenvironment in the recipient. 
The biological and molecular alterations within a hostile 
microenvironment such as that produced after a cardiac 
insult, may certainly influence the proliferative capacity 
of stem cells once injected (70, 162, 163). Therefore, 
a key question currently under clinical evaluation is 
the possibility to rejuvenate the target tissue (68). 
Accordingly, changing the microenvironment of the 
injection site may be useful to increase the engraftment 
of transplanted cells, but also their regenerative capacity 
has been targeted. It has been demonstrated in a model 
of hetero-chronic parabiosis, that circulating factors 
can “rejuvenate” hMSCs in the old parabiont (71). 
Specifically, the factors that seem to hold rejuvenating 
properties on aged hMSCs are linked to the circulating 
growth differentiation factors (71), including members 
of the transforming growth factor beta superfamily 
(VEGF and bFGF; 72, 73). These effects have been 
demonstrated both in vitro and in vivo after MI. To date 
a variety of factors delivered to the site of cell therapy 
injection locations have been exploited. Local injection 
of HMGB-1 increases the regeneration of infarcted 
myocardium by activating endogenous CSCs (165, 166). 
Transplantation of syngeneic cardiac fibroblasts stably 
overexpressing SDF-1, increases the homing of c-kit+ 
cells into the myocardium, which has also been shown 
to generate a stabilized SDF-1 mutant (167, 168). The 
overexpression of IGF-1 restricted to myocytes retards 
both aging of CPCs and myocytes, and the onset of 
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ventricular dysfunction (80). It has been demonstrated 
that age-dependent impairment of EPCs is corrected 
by growth-hormone-mediated IGF-1 increase, both in a 
preclinical animal model and in humans (139). Moreover, 
the delivery of IGF-1 injected locally into the myocardium 
through biotinylated peptide nanofibers, improves 
neonatal rat cardiomyocyte cell therapy after MI (81). 
The administration of PDGF, which is downregulated 
during aging, is able to reverse the senescent 
predisposition to increased cardiac injury (169). Other 
biological candidates have been recently discovered. For 
instance, the circulating extracellular domain of Klotho, 
a transmembrane protein that controls the sensitivity of 
cells to insulin which plays a main role in aging, has been 
postulated to act as an anti-aging hormone (170, 171). The 
overexpression of Klotho in mice extends lifespan (170) 
not by simply acting on insulin/IGF-1 signaling, but also 
by increasing oxidative stress resistance via the the 
upregulation of manganese superoxide dismutase and 
also acting as an essential cofactor of fibroblast growth 
factor signaling (172). Additionally, Klotho can influence 
the regenerative response of tissue-resident stem cells 
in multiple organs involving a more complex scenario. 
Finally, a novel rejuvenating approach consists low-
energy shock wave-induced tissue activation which 
stimulated the expression of SDF-1 and VEGF in the 
target tissue and promoted homing of intravenously 
infused EPCs in uninjured and chronically ischemic 
rats (173).
5. ALTERNATIVES TO AUTOLOGOUS CELL 
THERAPY
So far, cell therapy (not only in the cardiovascular 
field), has been mainly based on the employment of 
autologous stem cells, treated to enhance their potency 
or commitment in order to replace or regenerate the 
damaged tissue. Given the role of aging in recipients (69), 
the host environment plays an even more relevant role in 
the clinical outcome of the cell regenerative response to 
the ischemic injury.
Over the years autologous cell therapies 
have shown several limitations. The proliferative and 
regenerative capacity of progenitor cells decreases 
with age (174, 175), with a consistent reduced efficacy 
of progenitor cells from old patients. Another practical 
limitation consists in the collection of BM samples or 
biopsies from other sources that often require invasive 
procedures. As the low percentage of stem and 
progenitor cells in the starting material might occur, 
cells need to be expanded ex vivo before autologous 
applications. Such procedures may require days (176) 
or weeks (177), depending on the cell number needed 
and the age and comorbidities of the donor, as progenitor 
cells from old patients have reduced proliferation 
potential (90, 174, 175). To date, stem cell ex vivo 
expansion requires Good Manufacturing Practice (GMP) 
compliant facilities. Although safety and reproducibility 
is assured within cell factories, however, patient-specific 
tissue harvesting and cell preconditioning may result in a 
delayed start of the therapy, with a risk of the introduction 
of possible variations in cell potency related to patient 
age and disease (68, 178, 179).
One possibility to improve the efficacy of stem 
cell therapy is represented by the use of allogeneic 
cells. Allogeneic cell therapy from young donors have 
several advantages over autologous, including a higher 
regenerative potential (180) and availability for clinical 
use at any time. Moreover, cells from a single donor can 
be used for many patients, thus tremendously reducing 
the manufacturing costs of cell products. In this scenario, 
we could hypothesize the employment of young cells in 
aged patients or healthy cells in patients with metabolic 
diseases (such as diabetes or metabolic syndrome) 
to overcome the decreased activity of the respective 
autologous cells.
Allogeneic CDC transplantation without 
concomitant immunosuppression has been demonstrated 
to be safe (181, 182) and promotes cardiac regeneration, 
improving heart function and endogenous repair 
mechanisms in a rat MI model (178). CDCs have a 
low immunomodulatory profile and their allogeneic 
transplantation only induces a transient mild local immune 
reaction in a rat MI model. The biological and functional 
benefits of such a strategy, almost indistinguishable 
from syngeneic transplantation, could persist 6 months 
post-MI (178).
In addition, MSCs have been shown to 
inhibit T-cell responses through the modulation of 
B cells and antigen-presenting cells (183-185), to 
induce a local immunosuppressive environment 
through the production of prostaglandins and anti-
inflammatory cytokines (186, 187), and to inhibit 
lymphocyte proliferation, dendritic cell maturation and 
alloimmune rejection (186, 188-193). Due to their 
immunomodulatory properties, MSCs have been 
tested in initial clinical studies of graft versus-host 
diseases (194), osteogenesis imperfecta (195), glycogen 
storage diseases (196), Crohn’s disease (197) and 
organ transplantation (26, 27, 198). In fact, adult human 
MSCs express intermediate levels of MHC-I but do not 
express human leukocyte antigen (HLA) class II (16) or 
co-stimulatory molecules on the cell surface under normal 
in vitro conditions. However, HLA-II has been detected 
in lysates of unstimulated MSCs, presumably reflecting 
intracellular deposits of the antigen. Treatment with 
interferon-γ has been found to induce the expression of 
HLA class II on the cell surface (189). Another study has 
shown that MSCs express MHC-II as antigen presenting 
cells in presence of low levels of interferon-γ, whereas 
high levels of interferon-γ impair its expression (199).
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Despite this, the potential immunogenicity of 
allogeneic MSCs remains an unresolved issue that may 
affect their clinical efficacy. In fact, it has been shown 
that although MSCs actively inhibit rejection (200), they 
might be immune-rejected upon cardiac differentiation 
in the injured heart (201). Again, both allogeneic MSCs 
and autologous cells have been shown to improve 
cardiac function 1 month after MI in a rat MI model (201). 
However, 6 months after infarction, the allogeneic MSCs 
were rejected, resulting in decreased heart function. If 
MSCs were in vivo pretreated with prostaglandin E2, 
allogeneic injection of MSCs still prevents rejection and 
ventricular function could be restored, thus highlighting 
the importance of the immune/inflammatory system in 
balancing cardiac repair (202).
The first Phase I, randomized, double-blinded, 
placebo-controlled, dose escalation clinical study (181), 
has demonstrated that delivery of MSCs is safe and 
elicits no allogeneic T-cell response. This trial has 
evaluated the effect of cell dosage, also showing that 
higher doses of stem cells may not always provide 
greater benefit (203 205). Authors have postulated 
that the biological effect of stem cell injection likely 
reaches a plateau, as lower cell doses have been 
found to display greater improvements in heart function, 
whereas higher cell concentrations could result in 
improved inflammatory responses, thus affecting cell 
performance (203). The POSEIDON trial has randomized 
30 patients with heart failure to receive either allogeneic 
or autologous mesenchymal stem cells (MSCs) by 
direct endomyocardial injection. Several studies have 
shown delayed host responses to allogeneic MSCs in 
vivo around 2 weeks after transplantation, suggesting 
that tolerance of MSCs across the allogeneic barrier 
may not be absolute (201, 206-208). Moreover, the 
trans-differentiation of MSCs into cardiac lineage cells 
in response to 5-azacytidine or cytokine treatment 
increased the expression of immunostimulatory 
MHC-Ia and MHC-II molecules and decreases the 
immunomodulatory MHC-IIb, resulting in enhanced 
cytotoxicity of MSCs in co-culture with allogeneic 
leukocytes (201). These observations suggest that MSCs 
can switch their immune states from immunomodulatory 
to immunostimulatory depending on the biological 
context (201).
6. CONCLUSIONS AND FUTURE 
PERSPECTIVES
It is hard to predict whether or not stem cell-
based therapies will represent a clinically reliable 
therapeutic strategy to fully restore cardiac function., 
The impact of diseases such as metabolic syndrome, 
diabetes and aging on endogenous stem/progenitor cells 
and on cardiac microenvironment may limit the benefits 
of cell therapy.
So far, cell-based therapy has been extensively 
studied in animal models, using the abovementioned 
cell populations. Most of the clinical trials have only 
tested the safety and efficacy of autologous adult stem 
cells. A progressive research approach in preclinical 
and clinical studies is needed to ensure the realization 
of cardiac regeneration by allogeneic cell therapy. The 
allogeneic scenario may offer the advantage of collecting 
young and healthy “universal donor cells” (209), and to 
expand the cells in advance in dedicated and controlled 
GMP-facilities. This would allow the potential to obtain an 
unlimited number of doses for clinical administration and 
even to treat acute diseases such as MI. Additionally, the 
employment of a specific stem cell population showing 
low immunogenic properties would avoid the use of 
immunosuppressive treatment. To date, several issues 
remain unresolved. Experimental evidence suggest 
that even in vivo allogeneic transplanted MSCs may 
switch to different immune states, inducing alloimmune 
rejection (201). Therefore, minimizing donor-recipient 
HLA-II mismatch might represent a good strategy in order 
to attenuate alloimmune rejection of transplanted MSCs. 
In line with this, very promising studies are focusing on the 
establishment of a GMP HLA homozygous haplobanks 
which should overcome the issue of HLA mismatch in the 
context of cell-based transplants (210).
In addition, the low retention and engraftment 
of stem cells within damaged cardiac tissue after clinical 
administration requires a better definition of the biological 
mechanisms underlying such processes. Nevertheless, 
given the key role of stem cell paracrine action as a major 
mechanism involved in immune rejection after in vivo 
injection, a long-term survival of transplanted stem cells 
may not be necessary to achieve long-lasting clinical 
effects (211). In the future the “off the shelf” cell therapy 
product could become a reality, by developing human 
pluripotent stem cell bio-banks with low immunogenic 
properties and high regenerative capacity (212).
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